Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump inhibitor in original prescription formulation
- Viddler
Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump inhibitor in original prescription formulation
Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump inhibitor in original prescription formulation. Novartis announced today that Prevacid® 24HR (lansoprazole delayed-release capsules 15 mg) has been approved by the U.S. Food and Drug Administration (FDA) as the first over-the-counter (OTC) Proton Pump Inhibitor (PPI) for the treatment of frequent heartburn since 2003. Prevacid 24HR is expected to be available over-the-counter in 2009. To view Multimedia News Release, go to http://www.prnewswire.com/mnr/prevacid/38457/ By multivu Tags : 24hr , 38457 , approved , fda , frequent , heartburn , lansoprazole , multivu , novartis , otc , ppi , prevacid , treatment
Viddler | May 15, 2009
Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump...
Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump...
Novartis receives approval from FDA to market Prevacid(R)...
Novartis receives approval from FDA to market Prev...
Novartis receives approval from FDA to market Prevacid(R) 24HR as first and only OTC proton pump inh
TAXUS Liberté Paclitaxel-Eluting Stent expanding in a coronary artery
Previous Page
Next Page
